ABSTRACT
Introduction Pulmonary vascular distensibility associates with right ventricular function and clinical outcomes in patients with unexplained dyspnea and pulmonary hypertension. Alpha distensibility coefficient is determined from a non-linear fit to multipoint pressure-flow plots. The study aims were 1) to create and test a user-friendly tool to standardize analysis of exercise hemodynamics including distensibility and 2) to investigate changes in distensibility following treatment in patients with pulmonary arterial hypertension.
Methods Participants with repeat exercise right heart catherization and PAH were identified from the University of Arizona PH Registry (n=29). Single-beat analysis was used to quantify right ventricular function including the coupling ratio and diastolic stiffness. Prototypes of the iCPET calculator were developed using Matlab, Python and RShiny to analyze exercise hemodynamics and alpha distensibility coefficient, α (%/mmHg) from multi-point pressure flow plots. Interclass coefficients were calculated for inter-platform and interobserver variability in alpha.
Results No significant bias in the intra-platform (Matlab vs RShiny: ICC: 0.996) or inter-observer (ICC: 0.982) comparison of alpha values. Participants with PAH had a significant decrease in afterload at follow-up (p<0.05) but no significant change in alpha distensibility. At follow-up, participants with a resting mean PA pressure < 25 mmHg had no change in pressure, resistance or alpha distensibility. Alpha distensibility significantly correlated with PA compliance at both the index and follow-up visit.
Discussion The iCPET calculator standardizes alpha distensibility calculations. In this retrospective cohort, alpha distensibility did not change despite a decrease in pulmonary vascular afterload (PVR and mPAP) at follow-up after treatment with pulmonary vasodilators.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Archie Clifford and Clara Mabel Rentfrow Heart Disease Fund and the Mark and Emma Schiffman Research Fund from the University of Arizona Sarver Heart Center. This work was also supported by an AHA Career Development Award (19CDA34730039).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board at the University of Arizona (IRB Protocol no. 1100000621).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is available upon request.
